⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OCUL News
Ocular Therapeutix, Inc.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
OCUL
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
globenewswire.com
OCUL
2026 Back of the Eye Disorders Market Research Report (2nd Edition): A Development Pipeline Consisting of ~690 Approved or Clinical-Stage Therapeutic Candidates
globenewswire.com
KODK
OTLK
ALDX
OCUL
REGN
ABBV
NVS
BHC
SUN
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
globenewswire.com
OCUL
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
OCUL
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
OCUL
Form 8-K
sec.gov
OCUL
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
globenewswire.com
OCUL
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
OCUL
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
globenewswire.com
OCUL